Healthcare entity
regulation is the sole category represented across all 3 tracked stories. Of the tracked stories, 2 of 3 also mention America First Policy Institute, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.5 for the broader beat in this window.
Last mentioned: 4d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 3 tracked stories. Of the tracked stories, 2 of 3 also mention America First Policy Institute, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.5 for the broader beat in this window. That works out to roughly 0.1 stories per week across a 164-day span. The 6.7 average consequence score is above the beat benchmark of 6 in the same window. We currently track 3 Healthcare stories that mention Marty Makary, published between March 10, 2026 and August 20, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 897 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Marty Makary. Shared-story counts are live from our verified record — not editorial picks.
Trump announces Heidi Overton as FDA Commissioner nominee
President Trump names the White House Domestic Policy Council deputy director to lead the FDA, pending Senate confirmation.
Marty Makary resigns as FDA Commissioner
The previous FDA head leaves behind unfinished projects on ultraprocessed foods, antidepressants, and COVID-19 shots.
For health IT, medical device and telehealth leaders, Overton's nomination signals a period of regulatory uncertainty. Her backing of MAHA and most favored nation drug pricing could reshape digital health evidence standards, diagnostics oversight and vaccine-adjacent software, even as deregulatory forces promise faster approvals. Confirmation will test how the FDA balances innovation with public health safeguards.
A White House health-policy aide with a hand in the childhood vaccine-schedule rewrite is tapped to run the FDA during a multistate cyclospora outbreak. Health systems and public-health officials now weigh the operational impact of leadership churn and a nominee whose recommendations physicians say lack scientific support.
Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA's handling of biologic therapy applications for rare diseases, specifically targeting Duchenne muscular dystrophy. The probe follows a direct consultation with FDA Commissioner Marty Makary regarding perceived regulatory barriers for life-saving treatments.
Marty Makary is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
